Authorized purpose: Provides computer-assisted triage and notification for CTA abdomen studies with suspected abdominal aortic aneurysms.
Clinical role
Automatically analyzes abdominal CTA for suspected abdominal aortic aneurysm and highlights suspect studies in a standalone mobile application for study-list prioritization in parallel to standard of care; specialists reading the original images make the diagnostic decision.
Images and patients
CT/CTA · Abdomen/abdominal aorta
Key limitation
Keep in mind: Not diagnostic and not for confirmation or replacement of full evaluation; the reviewed scope is infra-renal fusiform aneurysms at least 3 cm.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provides computer-assisted triage and notification for CTA abdomen studies with suspected abdominal aortic aneurysms.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Abdomen/abdominal aorta Input: CTA images of the abdomen from DICOM-compatible imaging devices and modalities.
Who uses it?Intended users: Hospital networks and vascular or endovascular specialists.
What does the software produce?Output: Suspected-aneurysm study highlighting and worklist prioritization with informational, non-diagnostic compressed preview images.
What is its most important limitation?Key limitation: Not diagnostic and not for confirmation or replacement of full evaluation; the reviewed scope is infra-renal fusiform aneurysms at least 3 cm.
Clinical takeaway. Clinical role: Provides computer-assisted triage and notification for CTA abdomen studies with suspected abdominal aortic aneurysms.
Evidence takeaway. Evidence from the reviewed source record: FDA reported 466 CTA scans from two US sites, including 167 AAA-positive and 299 negative scans, with sensitivity 96%, specificity 95%, and AUC 0.99.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provides computer-assisted triage and notification for CTA abdomen studies with suspected abdominal aortic aneurysms.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Automatically analyzes abdominal CTA for suspected abdominal aortic aneurysm and highlights suspect studies in a standalone mobile application for study-list prioritization in parallel to standard of care; specialists reading the original images make the diagnostic decision.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The software automatically receives and analyzes CT angiogram (CTA) imaging of the abdomen for the presence of an aortic aneurysm using an artificial intelligence algorithm" … "studies determined by the algorithm to contain a suspected abdominal aortic aneurysm are highlighted in the standalone mobile application for study list prioritization or triage in parallel to ongoing standard of care.". Read from the exact FDA decision document on 2026-11-14.
Used by hospital networks and vascular or endovascular specialists during routine patient care on CTA images of the abdomen; the FDA document does not state an indicated patient population.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The device is intended to assist hospital networks and vascular or endovascular specialists in workflow triage by flagging and prioritizing studies with suspected abdominal aortic aneurysms during routine patient care." … "Viz AAA is a radiological computer-assisted triage and notification software device for analysis of CTA images of the abdomen.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA reported 466 CTA scans from two US sites, including 167 AAA-positive and 299 negative scans, with sensitivity 96%, specificity 95%, and AUC 0.99.
FDA source
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Viz AAA regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K223443
Samplen=466
Sites2
IndependenceIndependence not established
K223443
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223443. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CTA images of the abdomen from DICOM-compatible imaging devices and modalities.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes images acquired during patient care being forwarded to Viz.ai's Backend server for analysis by the AI algorithm, with a mobile software module implemented in Viz.ai's Viz VIEW mobile viewing application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Images acquired during patient care are forwarded to Viz.ai’s Backend server where they are analyzed by the Viz AAA artificial intelligence algorithm for an abdominal aortic aneurysm." … "The Viz AAA mobile software module is implemented into Viz.ai’s generic non-diagnostic DICOM image mobile viewing application, Viz VIEW, which displays CTA scans that are sent to the Backend server.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Suspected-aneurysm study highlighting and worklist prioritization with informational, non-diagnostic compressed preview images.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Suspected-aneurysm study highlighting and worklist prioritization with informational, non-diagnostic compressed preview images.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes images acquired during patient care being forwarded to Viz.ai's Backend server for analysis by the AI algorithm, with a mobile software module implemented in Viz.ai's Viz VIEW mobile viewing application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Images acquired during patient care are forwarded to Viz.ai’s Backend server where they are analyzed by the Viz AAA artificial intelligence algorithm for an abdominal aortic aneurysm." … "The Viz AAA mobile software module is implemented into Viz.ai’s generic non-diagnostic DICOM image mobile viewing application, Viz VIEW, which displays CTA scans that are sent to the Backend server.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Viz.ai's trust center describes an independently audited security and privacy program: SOC 2 Type II scoped to Viz.ai production systems and supporting infrastructure, a HIPAA compliance program with third-party risk assessments, ISO 27001, 27701, 27799, 27017/27018, 22301, 27035, and 42001 certifications, GDPR program with EU-US Data Privacy Framework participation, encryption in transit and at rest, defense-in-depth architecture, and continuous monitoring via Drata.
Vendor-wide
Checked 2026-10-27
Vendor statement; the SOC 2 report and certificates were not read (request-gated via the trust center). Applicant name variants ('Viz. ai, Inc.', 'Viz.Al, Inc.') are bridged via the identical distinctive name and Viz product naming (Viz AAA, ContaCT). Exact-release scope is not established.
Viz.ai's trust center states that its assurance program includes continuously monitored controls, SOC 2 Type II coverage that includes the availability criterion for Viz.ai production systems and supporting infrastructure, ISO 22301 business continuity certification to ensure uninterrupted clinical workflows, and ISO 27035 incident management certification.
Vendor-wide
Checked 2026-10-27
Vendor statements, not attestations. Certificates and audit reports were not read; the trust center names Viz.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K223443 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.